Poster Presentation Reviews the Hemopurifier®
Affinity Resin's
Ability to Bind Extracellular Vesicles in Long
COVID Samples
SAN
DIEGO, June 9, 2025 /PRNewswire/ -- Aethlon
Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused
on developing products to treat cancer and life-threatening
infectious diseases, today announced that an abstract has been
accepted for poster presentation at the Keystone Symposium on Long
COVID and Other Post-Acute Infection Syndromes being held at
Eldorado Hotel & Spa, Santa Fe,
NM, United States, August
10-13,2025
(https://www.keystonesymposia.org/conferences/conference-listing/meeting/program-highlights/F12026).
Long COVID refers to persistent symptoms following acute
SARs-CoV-2 infection (COVID-19). These symptoms - including
fatigue, post-exertional malaise, shortness of breath, chest pain
and cognitive difficulties such as "brain fog" - may last for weeks
or months after the initial illness. Long COVID is estimated to
affect between 44 and 48 million people in the United States alone with a projected
economic burden of $2 billion for
those with symptoms lasting a year. Despite over $1 billion allocated to Long COVID research
funding, no treatment has proven effective.
Extracellular vesicles (EVs), nanoparticles 50-500nm in
diameter, released from all cell types and involved in cell-to-cell
communication, have been implicated in the pathogenesis of Long
COVID. EVs have been found to contain viral particles and
other cargo associated with abnormal blood clotting and
inflammation.
Aethlon Medical's Hemopurifier® is an investigational
extracorporeal device designed to bind and remove harmful EVs from
the blood through a combination of plasma separation, size
exclusion and binding to a proprietary affinity resin containing
the plant lectin Galanthus nivalis agglutinin (GNA),
previously found to bind to the sugar mannose.
The Hemopurifier has previously been shown to remove EVs in a
patient with severe acute COVID-19 infection. Aethlon Medical
collaborated with the University of California
San Francisco Medical Center Long
COVID clinic to evaluate plasma samples from participants
with Long COVID and control participants who had fully recovered
from COVID-19 in order to examine whether individuals
with Long COVID would have EVs with the mannose target on their
surface that would bind to the affinity resin in the device. The
data to be presented will review the binding of both larger and
smaller EVs to GNA lectin and the lectin-based affinity resin,
respectively.
Presentation details and times are as follows:
Title: Extracellular Vesicles from Participants with
Long COVID are Mannosylated and Bind to the Galanthus Nivalis
Agglutinin Resin in the Aethlon Hemopurifier®
Authors: Miguel
Pesqueira1, Rosalia de
Necochea Campion1, Thomas
Dalhuisen2, Emily A.
Fehrman2, Jeffrey N.
Martin2, Timothy J.
Henrich2, Steven G.
Deeks2, Michael J.
Peluso2, Steven P.
LaRosa1
- Aethlon Medical Inc., San Diego,
CA, USA
- University of California, San
Francisco, San Francisco,
CA, USA
Presenter: Steven P.
LaRosa, M.D, Chief Medical Officer, Aethlon Medical,
Inc.
Poster Number: 2001
Date and Time: August 12, 2025, 1930, MDT.
This poster will be available following the meeting on the
Aethlon Medical, Inc. corporate website at
https://www.aethlonmedical.com/.
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company focused on
developing the Hemopurifier, a clinical stage immunotherapeutic
device which is designed to combat cancer and life-threatening
viral infections and for use in organ transplantation. In human
studies, the Hemopurifier has demonstrated the removal of
life-threatening viruses and in pre-clinical studies, the
Hemopurifier has demonstrated the removal of harmful EVs from
biological fluids, utilizing its proprietary lectin-based
technology. This action has potential applications in cancer, where
EVs may promote immune suppression and metastasis, and in
life-threatening infectious diseases. The Hemopurifier is a U.S.
Food and Drug Administration (FDA) designated Breakthrough Device
indicated for the treatment of individuals with advanced or
metastatic cancer who are either unresponsive to or intolerant of
standard of care therapy, and with cancer types in which EVs have
been shown to participate in the development or severity of the
disease. The Hemopurifier also holds an FDA Breakthrough Device
designation, and an open Investigational Device Exemption (IDE)
application related to the treatment of life-threatening viruses
that are not addressed with approved therapies.
Additional information can be found at
www.AethlonMedical.com.
Company Contact:
Jim Frakes
Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
View original
content:https://www.prnewswire.com/news-releases/aethlon-medical-to-present-new-pre-clinical-data-at-the-keystone-symposium-on-long-covid-and-other-post-acute-infection-syndromes-302475948.html
SOURCE Aethlon Medical, Inc.